1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424.
2. Bogos K, Kiss Z, Gálffy G, Tamási L, Ostoros G, Müller V, et al. Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary. Frontiers in Oncology. 2019;9(1051).
3. Zheng R, Zeng H, Zuo T, Zhang S, Qiao Y, Zhou Q, et al. Lung cancer incidence and mortality in China, 2011. Thorac Cancer. 2016;7(1):94-9.
4. Chen WQ, Zuo TT, Zheng RS, Zeng HM, Zhang SW, He J. [Lung cancer incidence and mortality in China in 2013]. Zhonghua Zhong Liu Za Zhi. 2017;39(10):795-800.
5. Raaschou-Nielsen O, Andersen ZJ, Beelen R, Samoli E, Stafoggia M, Weinmayr G, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). The Lancet Oncology. 2013;14(9):813-22.
6. Cai W-Y, Wei T-Z, Luo Q-C, Wu Q-W, Liu Q-F, Yang M, et al. The Wnt–β-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. Journal of Cell Science. 2013;126(13):2877-89.
7. Chang W, Wang H, Kim W, Liu Y, Deng H, Liu H, et al. Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis. Cell stem cell. 2020;26(5):739-54.e8.
8. Sini C, Tuzi A, Rossi G, Russo A, Pezzuto A. Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncol. 2018;14(13s):29-40.
9. Jeong H, Phan ANH, Choi JW. Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Pharmacogn Mag. 2017;13(52):595-9. PMCID: 5701397.
10. Wang H, Lu B, Ren S, Wu F, Wang X, Yan C, et al. Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44. Molecular Therapy - Nucleic Acids. 2020;19:218-27.
11. Shu D, Xu Y, Chen W. Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. J Drug Target. 2019:1-7.
12. He J, Jin S, Zhang W, Wu D, Li J, Xu J, et al. Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression. J Cancer. 2019;10(24):6003-13. PMCID: 6856583.
13. Wang M, Yu F, Wu W, Zhang Y, Chang W, Ponnusamy M, et al. Circular RNAs: A novel type of non-coding RNA and their potential implications in antiviral immunity. International Journal of Biological Sciences. 2017;13(12):1497-506.
14. Liu Y, Cheng Z, Pang Y, Cui L, Qian T, Quan L, et al. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. Journal of Hematology & Oncology. 2019;12(1):51.
15. Sulaiman SA, Muhsin NIA, Jamal R. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Front Physiol. 2019;10:279-.
16. Pang Y, Mao C, Liu S. Encoding activities of non-coding RNAs. Theranostics. 2018;8(9):2496-507.
17. Li X, Wang M, Du N, Liang T, Xiao G-D, Li K, et al. Matrine Inhibitory Effect on Self-renewal and Re-sensitization of 5-FU Resistant NSCLC Stem Cells were through Let-7b dependent Downregulation of CCND1. Cell Cycle. 2020;19(23):3249-59.
18. Shabaninejad Z, Vafadar A, Movahedpour A, Ghasemi Y, Namdar A, Fathizadeh H, et al. Circular RNAs in cancer: new insights into functions and implications in ovarian cancer. Journal of Ovarian Research. 2019;12(1):84.
19. Zhou R, Chen KK, Zhang J, Xiao B, Huang Z, Ju C, et al. The decade of exosomal long RNA species: an emerging cancer antagonist. Molecular Cancer. 2018;17(1):75.
20. Xie F, Huang C, Liu F, Zhang H, Xiao X, Sun J, et al. CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression. Molecular Cancer. 2021;20(1).
21. Rickert D, Bartl J, Picard D, Bernardi F, Qin N, Lovino M, et al. Circular RNA profiling distinguishes medulloblastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma. Acta Neuropathologica. 2021;141(6):975-8.
22. Huang H, Weng H, Chen J. m(6)A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer cell. 2020;37(3):270-88. PMCID: 7141420.
23. Zhang H, Xiao X, Wei W, Huang C, Wang M, Wang L, et al. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer. Molecular Cancer. 2021;20(1).
24. Si W, Li Y, Ye S, Li Z, Liu Y, Kuang W, et al. Methyltransferase 3 Mediated miRNA m6A Methylation Promotes Stress Granule Formation in the Early Stage of Acute Ischemic Stroke. Front Mol Neurosci. 2020;13:103. PMCID: 7289951.
25. Huang G, Wang M, Li X, Wu J, Chen S, Du N, et al. TUSC7 suppression of Notch activation through sponging MiR-146 recapitulated the asymmetric cell division in lung adenocarcinoma stem cells. Life Sci. 2019;232:116630.
26. Ito T, Kudoh S, Ichimura T, Fujino K, Hassan WA, Udaka N. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1. Hum Cell. 2017;30(1):1-10.
27. Nowell CS, Radtke F. Notch as a tumour suppressor. Nature Reviews Cancer. 2017;17(3):145-59.
28. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. PMCID: 4160307.
29. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery. 2012;2(5):401.
30. Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Research and Treatment. 2016;160(3):439-46.
31. Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322-33. PMCID: 5226511.
32. Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Őrfi L, Iwamoto T, et al. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Molecular Oncology. 2014;8(3):508-19.
33. Pan Z, Cai J, Lin J, Zhou H, Peng J, Liang J, et al. A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer. Molecular Cancer. 2020;19(1).
34. Lin X, Chai G, Wu Y, Li J, Chen F, Liu J, et al. RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nature Communications. 2019;10(1).
35. Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat Cell Biol. 2014;16(3):268-80.
36. Liu J, Zhang X, Chen K, Cheng Y, Liu S, Xia M, et al. CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1α-Mediated Glycolysis. Immunity. 2019;50(3):600-15.e15.
37. Wang X, Zhao Boxuan S, Roundtree Ian A, Lu Z, Han D, Ma H, et al. N6-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015;161(6):1388-99.
38. Arman K, Möröy T. Crosstalk Between MYC and lncRNAs in Hematological Malignancies. Frontiers in Oncology. 2020;10.
39. Wang C, Yang Y, Zhang G, Li J, Wu X, Ma X, et al. Long noncoding RNA EMS connects c-Myc to cell cycle control and tumorigenesis. Proc Natl Acad Sci U S A. 2019;116(29):14620-9. PMCID: 6642410.
40. Tokgun PE, Tokgun O, Kurt S, Tomatir AG, Akca H. MYC-driven regulation of long non-coding RNA profiles in breast cancer cells. Gene. 2019;714:143955.
41. Wang M, Li Y, Xiao GD, Zheng XQ, Wang JC, Xu CW, et al. H19 regulation of oestrogen induction of symmetric division is achieved by antagonizing Let-7c in breast cancer stem-like cells. Cell Prolif. 2019;52(1):e12534.
42. Sun X, Xu C, Tang SC, Wang J, Wang H, Wang P, et al. Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells. Cancer Gene Ther. 2016;23(4):83-9.
43. Sun X, Tang S-C, Xu C, Wang C, Qin S, Du N, et al. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1. Journal of Cellular and Molecular Medicine. 2015;19(6):1357-65.
44. Liu Y. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review. Cancer Biol Ther. 2018;19(6):445-9. PMCID: 5927699.
45. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-54.
46. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2017;378(2):113-25.
47. Song S-W, Lee H-S, Kim MS, Lee JM, Kim JH, Nam B-H, et al. Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection. The Annals of Thoracic Surgery. 2006;81(6):1974-81.
48. Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013;2:10-.
49. Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(8):1112-5. PMCID: 5885195.
50. Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014;7:513-24.
51. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer. 2017;17(11):637-58.
52. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. PMCID: 5817870.
53. Sun X, Li K, Zhao R, Sun Y, Xu J, Peng Z-Y, et al. Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations. Life Sciences. 2021;265:118797.
54. Xu C, Xiao G, Zhang B, Wang M, Wang J, Liu D, et al. CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade. Gene Ther. 2018;25(1):4-12.
55. Wang C, Yang Y, Zhang G, Li J, Wu X, Ma X, et al. Long noncoding RNA EMS connects c-Myc to cell cycle control and tumorigenesis. (1091-6490 (Electronic)).
56. Xiao G, Li X, Li G, Zhang B, Xu C, Qin S, et al. MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells. Oncotarget. 2017;8(61):103261-73. PMCID: 5732725.